Recent Insights into the Functions of the Retinoblastoma Susceptibility Gene Product

References

• Knudson A G, Jr. Mutation and cancer: Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971; 68: 820–823
   PubMed Web of Science ®Google Scholar
• Lee W-H, Bookstein R, Hong F, et al. Human retinoblastoma susceptibility gene: Cloning, identification, and sequence. Science 1987; 235: 1394–1399
   PubMed Web of Science ®Google Scholar
• Friend S H, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986; 323: 643–646
   PubMed Web of Science ®Google Scholar
• Fung Y-KT, Murphree A L, T'Ang A, et al. Structural evidence for the authenticity of the human retinoblastoma gene. Science 1987; 236: 1657–1661
   PubMed Web of Science ®Google Scholar
• Hong F D, Huang H, To H, et al. Structure of the human retinoblastoma gene. Proc Natl Acad Sci USA 1989; 86: 5502–5506
   PubMed Web of Science ®Google Scholar
• T'Ang A, Wu K, Hashimoto T, et al. Genomic organization of the human retinoblastoma gene. Oncogene 1989; 4: 401–407
   PubMed Web of Science ®Google Scholar
• McGee T L, Yandell D W, Dryja T P. Structure and partial genomic sequence of the human retinoblastoma susceptibility gene. Gene 1989; 80: 119–128
   PubMed Web of Science ®Google Scholar
• Eng C, Li F, Abramson D H, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Nail Cancer Inst 1993; 85: 1121–1128
   PubMed Web of Science ®Google Scholar
• Gallic B. Retinoblastoma gene mutations in human cancer. N Engl J Med 1994; 330: 786–787
   PubMed Web of Science ®Google Scholar
• Lee W-H, Shew J-Y, Hong F D, et al. The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 1987; 329: 642–645
   PubMed Web of Science ®Google Scholar
• Harbour J W, Lai S, Whang-Peng J, et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 1988; 241: 353–356
   PubMed Web of Science ®Google Scholar
• Horowitz J M, Park S, Bogenmann E, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 1990; 87: 2775–2779
   PubMed Web of Science ®Google Scholar
• Kaye F J, Kratzke R A, Gerster J L, et al. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc Natl Acad Sci USA 1990; 87: 6922–6926
   PubMed Web of Science ®Google Scholar
• Kratzke R A, Otterson G A, Hogg A, et al. Partial inactivation of the RB product in a family with incomplete penetrance of familial retinoblastoma and benign retinal tumors. Oncogene 1994; 9: 1321–1326
   PubMed Web of Science ®Google Scholar
• Friend S H, Horowitz J M, Gerber M R, et al. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumors: Organization of the sequence and its encoded protein. Proc Natl Acad Sci USA 1987; 84: 9059–9063
   PubMed Web of Science ®Google Scholar
• Horowitz J M, Yandell D W, Park S, et al. Point mutational inactivation of the retinoblastoma antioncogene. Science 1989; 243: 937–940
   PubMed Web of Science ®Google Scholar
• T'Aug A, Varley J M, Chakraborty S, et al. Structural rearrangement of the retinoblastoma gene in human breast cancer. Science 1988; 242: 263–266
   PubMed Web of Science ®Google Scholar
• Varley J M, Armour J, Swallow J E, et al. The retinoblastoma gene is frequently altered leading to loss of expression in primary breast tumours. Oncogene 1989; 4: 725–729
   PubMed Web of Science ®Google Scholar
• Bookstein R, Shew J, Chen P, et al. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 1990; 247: 712–715
   PubMed Web of Science ®Google Scholar
• Hensel C H, Hsieh C-L, Gazdar A F, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res 1990; 30: 3067–3072
   Google Scholar
• Lee E-HPY, To H, Shew J-Y, et al. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 1988; 241: 218–221
   PubMed Web of Science ®Google Scholar
• Reissmann P T, Simon M A, Lee W-H, et al. Studies of the retinoblastoma gene in human sarcomas. Oncogene 1989; 4: 839–843
   PubMed Web of Science ®Google Scholar
• Shew J, Chen P, Bookstein R, et al. Deletion of a splice donor site ablates expression of the following exon and produces an unphosphorylated RB protein unable to bind SV40 T antigen. Cell Growth Diff 1990; 1: 17–15
   PubMedGoogle Scholar
• Shew J, Lin B T, Chen P, et al. C-terminal truncation of the retinoblastoma gene product leads to functional inactivation. Proc Natl Acad Sci USA 1990; 87: 6–10
   PubMed Web of Science ®Google Scholar
• Toguchida J, Ishizaki K, Sasaki M S, et al. Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma. Nature 1989; 338: 156–158
   PubMed Web of Science ®Google Scholar
• Weichselbaum R R, Beckett M, Diamond A. Some retinoblastomas, osteosarcomas, and soft tissue sarcomas may share a common etiology. Proc Natl Acad Sci USA 1988; 85: 2106–2109
   PubMed Web of Science ®Google Scholar
• Scheffner M, Munger K, Byrne J C, et al. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Nail Acad Sci USA 1991; 88: 5523–5527
   PubMed Web of Science ®Google Scholar
• Takahashi R, Hashimoto T, Xu H-J, et al. The retinoblastoma gene functions as a growth and tumor suppressor in human bladder carcinoma cells. Proc Natl Acad Sci USA 1991; 88: 5257–5261
   PubMed Web of Science ®Google Scholar
• Huang H-JS, Yee J-K, Shew J-Y, et al. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 1988; 242: 1563–1566
   PubMed Web of Science ®Google Scholar
• Sumegi J, Uzvolgyi E, Klein G. Expression of the RB gene under the control of the MuL V-LTR suppresses tumorigenicity of WERI-Rb-27 retinoblastoma cells in immunodefective mice. Cell Growth Diff 1990; 1: 247–250
   PubMedGoogle Scholar
• Qin X-Q, Chittenden T, Livingston D M, et al. Identification of a growth suppression domain within the retinoblastoma gene product. Genes Dev 1992; 6: 953–964
   PubMed Web of Science ®Google Scholar
• Qin X-Q, Livingston D M, Ewen M, et al. The transcription factor E2F1 is a downstream target of RB action. Mol Biol Cell 1995; 15: 742–755
   Web of Science ®Google Scholar
• Qian Y, Luckey C, Horton L, et al. Biological function of the retinoblastoma protein requires distinct domains for hyperphosphorylation and transcription factor binding. Mol Cell Biol 1992; 12: 5363–5372
   PubMed Web of Science ®Google Scholar
• Hinds P W, Mittnacht S, Dulic V, et al. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 1992; 70: 993–1006
   PubMed Web of Science ®Google Scholar
• Whyte P, Buchkovich K J, Horowitz J M, et al. Association between an oncogene and an antioncogene: the adenovirus El A proteins bind to the retinoblastoma gene product. Nature 1988; 334: 124–129
   PubMed Web of Science ®Google Scholar
• Dyson N, Howley P M, Munger K, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934–937
   PubMed Web of Science ®Google Scholar
• DeCaprio J A, Ludlow J W, Figge J, et al. SV40 large T antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988; 54: 275–283
   PubMed Web of Science ®Google Scholar
• Dyson N, Bernards R, Friend S H, et al. Large T antigens of many polyomaviruses are able to form complexes with the retinoblastoma protein. J Virol 1990; 64: 1353–1356
   PubMed Web of Science ®Google Scholar
• Figge J, Webster T, Smith T F, et al. Prediction of similar transforming regions in simian virus 40 large T, adenovirus E1A, and myc oncoproteins. J Virol 1988; 62: 1814–1818
   PubMedGoogle Scholar
• Figge J, Smith T F. Cell-division sequence motif. Nature 1988; 334: 109
   PubMed Web of Science ®Google Scholar
• Nevins J R. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins. Science 1992; 258: 424–429
   PubMed Web of Science ®Google Scholar
• DeCaprio J A, Ludlow J W, Lynch D, et al. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell 1989; 58: 1085–1095
   PubMed Web of Science ®Google Scholar
• DeCaprio J A, Furukawa Y, Ajchenbaum F, et al. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc Natl Acad Sci USA 1992; 89: 1795–1798
   PubMed Web of Science ®Google Scholar
• Chen P, Scully P, Shew J, et al. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 1989; 58: 1193–1198
   PubMed Web of Science ®Google Scholar
• Mihara K, Cao X, Yen A, et al. Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 1989; 246: 1300–1303
   PubMed Web of Science ®Google Scholar
• Buchkovich K, Duffy L A, Harlow E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 1989; 58: 1097–1105
   PubMed Web of Science ®Google Scholar
• Ludlow J W, DeCaprio J A, Huang C, et al. SV40 Large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell 1989; 56: 57–65
   PubMed Web of Science ®Google Scholar
• Dorée M, Galas S. The cyclin dependent protein kinases and the control of cell division. FASEB J 1994; 8: 1114–1121
   PubMed Web of Science ®Google Scholar
• Lee M G, Nurse P. Complementation used to clone a human homologue of the fission yeast cell cycle control gene cdc2. Nature 1987; 327: 31–35
   PubMed Web of Science ®Google Scholar
• Ewen M E, Sluss H K, Sherr C J, et al. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 1993; 73: 487–497
   PubMed Web of Science ®Google Scholar
• Dowdy S F, Hinds P W, Louie K, et al. Physical interaction of the retinoblastoma protein with human D cyclins. Cell 1993; 73: 499–511
   PubMed Web of Science ®Google Scholar
• Kato J-Y, Matsushime H, Hiebert S W, et al. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase cdk4. Genes Dev 1993; 7: 331–342
   PubMed Web of Science ®Google Scholar
• Weinberg R A. The retinoblastoma protein and cell cycle control. Cell 1995; 81: 323–330
   PubMed Web of Science ®Google Scholar
• Ludlow J W, Shon J, Pipas J M, et al. The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from Sv40 large T. Cell 1990; 60: 387–396
   PubMed Web of Science ®Google Scholar
• Ludlow J W, Glendening C L, Livingston D M, et al. Specific enzymatic dephosphorylation of the retinoblastoma protein. Mol Cell Biol 1993; 13: 367–372
   PubMed Web of Science ®Google Scholar
• Hunter T, Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell 1994; 79: 573–582
   PubMed Web of Science ®Google Scholar
• Elledge S J, Harper J W. Cdk inhibitors: on the threshold of checkpoints and development. Curr Opin Cell Biol 1994; 6: 847–852
   PubMed Web of Science ®Google Scholar
• Guan K-L, Jenkins C W, Li Y, et al. Growth suppression by pi 8, a p16 INK4/MTS1 and p14 INK4B/MTS1-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev 1994; 8: 2939–2952
   PubMed Web of Science ®Google Scholar
• Serrano M, Gomez-Lahoz E, DePinho R A, et al. Inhibition of ras-induced proliferation and cellular transformation by p161NK4. Science 1995; 267: 249–252
   PubMed Web of Science ®Google Scholar
• El-Deiry W S, Tokino T, Velculescu V E, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825
   PubMed Web of Science ®Google Scholar
• Harper J W, Adami G R, Wei N, et al. The p21 Cdk-interacting protein CIP1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805–816
   PubMed Web of Science ®Google Scholar
• Xiong Y, Hannon G J, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701–704
   PubMed Web of Science ®Google Scholar
• Kuerbitz S J, Plunkett B S, Walsh W V, et al. Wild type p53 is a cells cycle chechpoint determinant following irradiation. Proc Natl Acad Sci USA 1992; 89: 7491–7495
   PubMed Web of Science ®Google Scholar
• Ewen M, Oliver C, Sluss H, et al. p53-Dependent repression of CDK4 translation in TGF-β-induced G1 cell-cycle arrest. Genes Dev 1995; 9: 204–217
   PubMed Web of Science ®Google Scholar
• Hannon G J, Beach D. p 15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994; 371: 257–261
   PubMed Web of Science ®Google Scholar
• Polyaak K, Lee M-H, Erdjument-Bromage H, et al. Cloning of p27Kipl, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimilogenic signals. Cell 1994; 78: 59–66
   PubMed Web of Science ®Google Scholar
• Kaelin W G, Ewen M E, Livingston D M. Definition of the minimal simian virus 40 large T antigen- and adenovirus E1A-finding domain in the retinoblastoma gene product. Mol Cell Biol 1990; 10: 3761–3769
   PubMed Web of Science ®Google Scholar
• Huang S, Wang N, Tseng B Y, et al. Two distinct and frequently mutated regions of retinoblastoma protein are required for binding to SV40 T antigen. EMBO J 1990; 9: 1815–1822
   PubMed Web of Science ®Google Scholar
• Hu Q, Dyson N, Harlow E. The regions of the retinoblastoma protein needed for binding to adenovirus El A or SV40 large T antigen are common sites for mutations. EMBO J 1990; 9: 1147–1155
   PubMed Web of Science ®Google Scholar
• Kaelin W G, Pallas D C, DeCaprio J A, et al. Identification of cellular proteins that can interact specifically with the T/E1A-binding region of the retinoblastoma gene product. Cell 1991; 64: 521–532
   PubMed Web of Science ®Google Scholar
• Huang S, Lee W-H, Lee Y-HP. A cellular protein that competes with SV40 T antigen for binding the retinoblastoma gene product. Nature 1991; 350: 160–162
   PubMed Web of Science ®Google Scholar
• Chittenden T, Livingston D M, Kaelin W G. The T/E1A-binding domain of the retinoblastom product can interact selectively with a sequence-specific DNA-binding protein. Cell 1991; 65: 1073–1082
   PubMed Web of Science ®Google Scholar
• Bandara L R, La Thangue N B. Adenovirus E1A prevents the retinoblastoma gene product from complexing with a cellular transcription factor. Nature 1991; 351: 494–497
   PubMed Web of Science ®Google Scholar
• Bagchi S, Weinmann R, Raychaudhuri P. The retinoblastoma protein copurifies with E2F-I, an E1A-regulated inhibitor of the transcription factor E2F. Cell 1991; 65: 1063–1072
   PubMed Web of Science ®Google Scholar
• Chellappan S P, Hiebert S, Mudryj M, et al. The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65: 1053–1061
   PubMed Web of Science ®Google Scholar
• Kovesdi I, Reichel R, Nevins J R. Identification of a cellular transcription factor involved in El A trans-activation. Cell 1986; 45: 219–228
   PubMed Web of Science ®Google Scholar
• La Thangue N B, Rigby P WJ. An adenovirus E1A-like transcription factor is regulated during the differentiation of murine embryonal carcinoma stem cells. Cell 1987; 49: 507–513
   PubMed Web of Science ®Google Scholar
• Farnham P J, Slansky J E, Kollmar R. The role of E2F in the mammalian cell cycle. Biochim Biophys Acta 1993; 1155: 125–131
   PubMed Web of Science ®Google Scholar
• Goodrich D W, Wang N P, Qian Y-W, et al. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 1991; 67: 293–302
   PubMed Web of Science ®Google Scholar
• Hiebert S W. Regions of the retinoblastoma gene product required for its interaction with the E2F transcription factor are necessary for E2 promoter repression and pRb-Mediated growth suppression. Mol Cell Biol 1993; 13: 3384–3391
   PubMed Web of Science ®Google Scholar
• Huang S, Shin E, Sheppard K-A, et al. The retinoblastoma protein region required for interaction with the E2F transcription factor includes the TVE1A binding and carboxyl-terminal sequences. DNA Cell Biol 1992; 7: 539–548
   Google Scholar
• Welch P J, Wang J YJ. C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-AM tyrosine kinase in the cell cycle. Cell 1993; 75: 779–790
   PubMed Web of Science ®Google Scholar
• Kim S-J, Wagner S, Liu F, et al. Retinoblastoma gene product activates expression of the human TGF-J32 gene through transcription factor ATF-2. Nature 1992; 358: 331–334
   PubMed Web of Science ®Google Scholar
• Wang C-Y, Petrynaik B, Thompson C B, et al. Regulation of an ETS-related transcription factor, Elf-1 binding to the retinoblastoma protein. Science 1993; 260: 1330–1335
   PubMed Web of Science ®Google Scholar
• Hagemeier C, Bannister A, Cook J. A, et al. The activation domain of transcription factor PU1 binds the retinoblastoma (RB) protein and the transcription factor TFIID in vitro: RB shows sequence similarity to TFIID and TFIIB. Proc Natl Acad Sci USA 1993; 90: 1580–1584
   PubMed Web of Science ®Google Scholar
• Shan B, Zhu X, Chen P-L, et al. Molecular cloning of cellular genes encoding retinoblastoma-associated proteins: identification of a gene with properties of the transcription factor E2F. Mol Cell Biol 1992; 12: 5620–5631
   PubMed Web of Science ®Google Scholar
• Gu W, Schneider J W, Condorelli G, et al. Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell 1993; 72: 309–324
   PubMed Web of Science ®Google Scholar
• Cavanaugh A H, Hempel W M, Taylor L J, et al. Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product. Nature 1995; 374: 177–180
   PubMed Web of Science ®Google Scholar
• Kaelin W G, Krek W, Sellers W R, et al. Expression cloning of a cDNA encoding a retinoblasloma-binding protein with E2F-like properties. Cell 1992; 70: 351–364
   PubMed Web of Science ®Google Scholar
• Helin K, Lees J A, Vidal M, et al. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 1992; 70: 337–350
   PubMed Web of Science ®Google Scholar
• Flemington E K, Speck S H, Kaelin W G. E2F-1 mediated transactivalion is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci USA 1993; 90: 6914–6918
   PubMed Web of Science ®Google Scholar
• Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma gene. Mol Cell Biol 1993; 13: 6501–6508
   PubMed Web of Science ®Google Scholar
• Lees J A, Saito M, Vidal M, et al. The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol 1993; 13: 7813–7825
   PubMed Web of Science ®Google Scholar
• Ivey-Hoyle M, Conroy R, Huber H E, et al. Cloning and characterization of E2F-2, a novel protein with the biochemical properties of transcription factor E2F. Mol Cell Biol 1993; 13: 7802–7812
   PubMed Web of Science ®Google Scholar
• Beijersbergen R L, Kerkhoven R M, Zhu L, et al. E2F-4, a new member of the E2F gene family, has oncogenic activity and associates with p107 in vivo. Genes Dev 1994; 8: 2680–2690
   PubMed Web of Science ®Google Scholar
• Ginsberg D, Vairo G, Chittenden T, et al. E2F-4, a new member of the E2F transcription factor family, interacts with p107. Genes Dev 1994; 8: 2665–2679
   PubMed Web of Science ®Google Scholar
• Sardel C, Vidal M, Cobrinik D, et al. E2F-4 and E2F-5, two novel members of the E2F family, are expressed in the early phases of the cell cycle. Proc Natl Acad Sci USA 1995; 92: 2403–2407
   PubMed Web of Science ®Google Scholar
• Krek W, Livingston D M, Shirodkar S. Binding to DNA and retinoblastoma gene product promoted by complex formation of different E2F family members. Science 1993; 262: 1557–60
   PubMed Web of Science ®Google Scholar
• Helin K, Wu C-L, Fattaey A R, et al. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative transactivation. Genes Dev 1993; 7: 1850–1861
   PubMed Web of Science ®Google Scholar
• Huber H E, Edwards G, Goodhart P J, et al. Transcription factor E2F binds DNA as a heterodimer. Proc Natl Acad Sci USA 1993; 90: 3525–3529
   PubMed Web of Science ®Google Scholar
• Girling R, Partridge J F, Bandara L R, et al. A new component of the transcription factor DRTF1/E2F1. Nature 1993; 362: 83–87
   PubMed Web of Science ®Google Scholar
• Wu C-L, Zukerberg L R, Ngwu C, et al. In vivo association of E2F and DP family proteins. Mol Cell Biol 1995; 15: 2536–2546
   PubMed Web of Science ®Google Scholar
• La Thangue N B. DRTF1/E2F1 :An expanding family of heterodimeric transcription factors implicated in cell-cycle control. Trends Biochem Sci 1994; 19: 108–114
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chellappan S P. Cloning and characterization of human DP2, a novel dimerization partner of E2F. Oncogene 1995; 10: 2085–2093
   PubMed Web of Science ®Google Scholar
• Jooss K, Lam E W, Bybee A, et al. Proto-oncogenic properties of the DP family of proteins. Oncogene 1995; 10: 1529–1536
   PubMed Web of Science ®Google Scholar
• Vairo G, Livingston D M, Ginsberg D. Functional interaction between E2F4 and p130: Evidence for distinct mechanisms underlying growth suppression by different Rb family members. Genes Dev Genes Dev 1995; 9: 869–881
   PubMed Web of Science ®Google Scholar
• Ewen M E, Xing Y, Lawrence J B, et al. Molecular cloning, chromosomal mapping, and expression of the cDNA for p107, a retinoblastoma gene product-related protein. Cell 1991; 66: 1155–1164
   PubMed Web of Science ®Google Scholar
• Hannon G J, Demetrick D, Beach D. Isolation of the Rb-related p130 through its interactions with CDK2 and cyclins. Genes Dev 1993; 7: 2378–2391
   PubMed Web of Science ®Google Scholar
• Cobrinik D, Whyte P, Peeper D S, et al. Cell cycle-specific association of E2F with the p130. E1A-binding protein. Genes Dev 1993; 7: 2392–2404
   PubMed Web of Science ®Google Scholar
• Schwarz J K, Devoto S H, Smith E J, et al. Interactions of the p107 and Rb proteins with E2F during the cell proliferation response. EMBOJ 1993; 12: 1013–1020
   PubMed Web of Science ®Google Scholar
• Smith E J, Nevins J R. The Rb relatedp 107 protein cansuppress E2F function Independently of binding to cyclin A/cdk2. Mol Cell Biol 1995; 15: 338–344
   PubMedGoogle Scholar
• Zamanian M, La Thangue N B. Transcriptional repression by the RB-related protein p107. Mol Biol Cell 1993; 4: 389–396
   PubMed Web of Science ®Google Scholar
• Zhu L, Van der Heuvel S, Helin K, et al. Inhibition of cell proliferation by p 107, a relative of the retinoblastoma protein. Genes Dev 1993; 7: 1111–1125
   PubMed Web of Science ®Google Scholar
• Claudio P P, Howard C M, Baldi A, et al. p130/pRb2 has growth suppression properties similar to yet distinctive from those of retinoblastoma family members pRb and p107. Cancer Res 1994; 54: 5556–5560
   PubMed Web of Science ®Google Scholar
• Lam E W-F, La Thangue N B. DP and E2F proteins: Coordinating trranscription with cell cycle progression. Curr Opin Cell Biol 1994; 6: 859–866
   PubMed Web of Science ®Google Scholar
• Shirodkar S, Ewen M, DeCaprio J A, et al. The transcription factor E2F interacts with the retinoblastoma product and a p107-cyclin A complex in a cell cycle-regulated manner. Cell 1992; 68: 157–166
   PubMed Web of Science ®Google Scholar
• Jacks T, Fazeli A, Schmitt E M, et al. Effects of an Rb mutation in the mouse. Nature 1992; 359: 295–300
   PubMed Web of Science ®Google Scholar
• Clarke A R, Maandag E R, Van Roon M, et al. Requirement for a functional Rb-1 gene in murine development. Nature 1992; 359: 328–330
   PubMed Web of Science ®Google Scholar
• Lee E Y-HP, Chang C-Y, Hu N, et al. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 1992; 359: 288–294
   PubMed Web of Science ®Google Scholar
• Johnson D G, Schwarz J K, Cress W D, et al. Expression of transcription factor E2F1 induces quiescent cells to enter S phase. Nature 1993; 365: 349–352
   PubMed Web of Science ®Google Scholar
• Qin X Q, Livingston D M, Kaelin W G, et al. Deregulated E2F1 expression leads to S-phase entry and p53-mediated apoptosis. Proc Natl Acad Sci USA 1994; 91: 10918–10922
   PubMed Web of Science ®Google Scholar
• Shan B, Lee W-H. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol Cell Biol 1994; 14: 8166–8173
   PubMedGoogle Scholar
• Singh P, Wong S, Hong W. Overexpression of E2F-1 in rat embryo fibroblasts leads to neoplastic transformation. EMBO J 1994; 13: 3329–3338
   PubMed Web of Science ®Google Scholar
• Xu G, Livingston D, Krek W. Multiple members of the E2F transcription factor family are the products of oncogenes. Proc Natl Acad Sci USA 1995; 92: 1357–1361
   PubMed Web of Science ®Google Scholar
• Johnson D, Cress W, Jakoi L, et al. Oncogenic capacity of the E2F1 gene. Proc Natl Acad Sci USA 1994; 91: 12823–12827
   PubMed Web of Science ®Google Scholar
• Weintraub S J, Prater C A, Dean D C. Retinoblastoma protein switches the E2F site from positive to negative element. Nature 1992; 358: 259–261
   PubMed Web of Science ®Google Scholar
• Neuman E, Flemington E K, Sellers W R, et al. Transcription of the E2F1 gene is rendered cell-cycle dependent by E2F DNA-binding sites within its promoter. Mol Cell Biol 1994; 14: 6607–6615
   PubMed Web of Science ®Google Scholar
• Johnson D G, Ohtani K, Nevins J R. Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev 1994; 8: 1514–1525
   PubMed Web of Science ®Google Scholar
• Hsiao K-M, McMahon S L, Farnham P. Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Genes Dev 1994; 8: 1526–1537
   PubMed Web of Science ®Google Scholar
• Lam E W-F, Watson R J. An E2F-binding site mediates cell-cycle regulated repression of mouse B-Myb transcription. EMBO 1993; 12: 2705–2713
   PubMed Web of Science ®Google Scholar
• Porcu P, Grana X, Li S, et al. An E2F binding sequence negatively regulates the response of the insulin-like growth factor I (IGF-I) promoter to simian virus 40T antigen and to serum. Oncogene 1994; 9: 2125–2134
   PubMed Web of Science ®Google Scholar
• Huber H E, Goodhart P J, Huang P S. Retinoblastoma protein reverses DNA bending by transcription factor E2F. J Biol Chem 1994; 9: 6999–7005
   Google Scholar
• Weintraub S J, Chow K NB, Luo R X, et al. Mechanism of active transcriptional repression by the retinoblastoma protein. Nature 1995; 375: 812–815
   PubMed Web of Science ®Google Scholar
• Adnane J, Shao Z, Robbins P D. The retinoblastoma susceptibility gene product represses transcription when directly bound to the promoter. J Biol Chem 1995; 270: 8837–8843
   PubMed Web of Science ®Google Scholar
• Sellers W R, Rodgers J, Kaelin W G. A potent transrepression domain in the retinoblastoma protein induces a cell-cycle arrest when bound to E2F sites. Proc Natl Acad Sci USA 1995; 92: 11544–11548
   PubMed Web of Science ®Google Scholar
• Bremner R, Cohen B L, Sopta M, et al. Direct transcriptional repression by pRB and its reversal by specific cyclins. Mol Cell Biol 1995; 15(61)3256–3265
   PubMedGoogle Scholar
• Shao Z, Ruppert S, Robbins P D. The retinoblastoma-susceptibility gene product binds directly to the human TATA-binding protein-associated factor TAFn250. Proc Natl Acad Sci USA 1995; 92: 3115–3119
   PubMed Web of Science ®Google Scholar
• Buckley M, Sweeney K, Hamilton J, et al. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993; 8: 2127–2133
   PubMed Web of Science ®Google Scholar
• Gillet C, Fantl V, Smith R, et al. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994; 54: 1812–1817
   PubMed Web of Science ®Google Scholar
• Hunter T, Pines J. Cyclins and cancer. Cell 1991; 66: 1071–1074
   PubMed Web of Science ®Google Scholar
• Jiang W, Zhang Y-J, Kahn S M, et al. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA 1993; 90: 9026–9030
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Pardee A. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 1993; 90: 1112–1116
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, O'Leary N, Molnar G, et al. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994; 54: 380–385
   PubMed Web of Science ®Google Scholar
• Leach F S, Elledge S J, Sherr C J, et al. Amplification of cyclin genes in colorectal carcinomas. Cancer Res 1993; 53: 1986–1989
   PubMed Web of Science ®Google Scholar
• Motokura T, Bloom T, Kim H G, et al. A novel cyclin encoded by a bell-linked candidate oncogene. Nature 1991; 350: 512–515
   PubMed Web of Science ®Google Scholar
• Motokura T, Arnold A. Cyclin D and oncogensis. Curr Opin Genet Dev 1993; 3: 5–10
   PubMedGoogle Scholar
• Schauer I, Siriwardana S, Langan T, et al. Cyclin D1 overexpression vs. retinoblastoma inactivation: Implications for growth control evasion in non-small cell and small cell lung cancer. Proc Natl Acad Sci USA 1994; 91: 7827–7831
   PubMed Web of Science ®Google Scholar
• Bartkova J, Lukas J, Muller H, et al. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994; 57: 353–361
   PubMed Web of Science ®Google Scholar
• Musgrove E, Lee C, Buckley M, et al. Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 1994; 91: 8022–8026
   PubMed Web of Science ®Google Scholar
• Tarn S, Theodoras A M, Shay J W, et al. Different expression and regulation of cyclin D1 in normal and tumor human cells: Association with cdk4 is required for cyclin D1 function in G1 progression. Oncogene 1994; 9: 2663–2674
   PubMed Web of Science ®Google Scholar
• Shapiro G I, Edwards C D, Kobzik L, et al. Reciprocal Rb inactivation and pi 6 expression in human lung carcinoma. Cancer Res 1995; 55: 505–509
   PubMed Web of Science ®Google Scholar
• Wang T, Cardiff R, Zukerberg L, et al. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 trangenic mice. Nature 1994; 369: 669–671
   PubMed Web of Science ®Google Scholar
• Lovec H, Sewing A, Lucibello F C, et al. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: Link between cell cycle control and malignant transformation. Oncogene 1994; 9: 323–326
   PubMed Web of Science ®Google Scholar
• Hinds P W, Dowdy S F, Eaton E N, et al. Function of a human cyclin gene as an oncogene. Proc Natl Acad Sci USA 1994; 91: 709–713
   PubMed Web of Science ®Google Scholar
• Lukas J, Muller H, Bartkova J, et al. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Biol 1994; 125: 625–638
   PubMed Web of Science ®Google Scholar
• Khatib Z A, Matsushime H, Valentine M, et al. Coamplification of the CDK4 gene with MDM2 and GL1 in human sarcomas. Cancer Res 1993; 53: 5535–5541
   PubMed Web of Science ®Google Scholar
• He J, Allen J R, Collins V P, et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletions in glioma cell lines. Cancer Res 1994; 54: 5804–5807
   PubMed Web of Science ®Google Scholar
• Cairns P, Mao L, Merlo A, et al. Rates of p16(MTS 1) mutations in primary tumors with 9p loss. Science 1994; 265: 415–417
   PubMed Web of Science ®Google Scholar
• Otterson G, Kratzke R, Coxon A, et al. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retails wildtype RB. Oncogene 1994; 9: 3375–3378
   PubMed Web of Science ®Google Scholar
• Okamoto A, Demetrick D, Spillare E, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 1994; 91: 11045–11049
   PubMed Web of Science ®Google Scholar
• Mori T, Miura K, Aoki T, et al. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 1994; 54: 3396–3397
   PubMed Web of Science ®Google Scholar
• Spruck I CH, Gonzalez-Zulueta M, Shibata A, et al. p16 gene in uncultured tumours. Nature 1994; 370: 183–184
   PubMed Web of Science ®Google Scholar
• Kamb A, Shattuck-Eidens D, Eeles R, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 1994; 8: 22–26
   Web of Science ®Google Scholar
• Hussussian C, Struewing J, Goldstein A, et al. Germline p16 mutations in familial melanoma. Nature Genet 1994; 8: 15–21
   PubMed Web of Science ®Google Scholar
• Caldas C, Hahn S, Da Costa L, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 1994; 8: 27–32
   PubMed Web of Science ®Google Scholar
• Okamoto A, Demetrick D, Spillare E, et al. Mutations and altered expression of p16. Proc Natl Acad Sci USA 1994; 91: 11045–11049
   PubMed Web of Science ®Google Scholar
• Wu X, Levine A J. p53 and E2F1 cooperate to mediate apoplosis. Proc Natl Acad Sci USA 1994; 91: 3602–3606
   PubMed Web of Science ®Google Scholar
• Jiang D, Srinivasan A, Lozano G, et al. SV40 T antigen abrogates p53-mediated transcriptional activity. Oncogene 1993; 8: 2805–2812
   PubMed Web of Science ®Google Scholar
• Segawa K, Minowa A, Sugaswa K, et al. Abrogation of p53-medi-ated transactivation by SV40 large T antigen. Oncogene 1993; 8: 543–548
   PubMed Web of Science ®Google Scholar
• Bargonetti J, Reynisdottir I, Friedman P N, et al. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev 1992; 6: 1886–1898
   PubMed Web of Science ®Google Scholar
• Mietz J A, Unger T, Huibregtse J M, et al. The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16E6 oncoprotein. EMBO J 1992; 11: 5013–5020
   PubMed Web of Science ®Google Scholar
• Yew P R, Berk A J. Inhibition of p53 transactivation required for transformation by adenovirus early E1B protein. Nature 1992; 357: 82–85
   PubMed Web of Science ®Google Scholar
• Hoppe-Seyler F, Butz K. Repression of endogenous p53 transactivation function in HeL a cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. Mol Cell Biol 1993; 67: 3111–3117
   Google Scholar
• Scheffner M, Wemess B A, Huibregtse J M, et al. The E6 oncoprotein encoded by human papillomaviruses types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129–1136
   PubMed Web of Science ®Google Scholar
• Band V, Dalai S, Delmolino L, et al. Enhanced degradation of p53 protein in HPV-E6 and BPV-1 E6 immortalized human mammary epithelial cells. EMBOJ 1993; 12: 1847–1852
   PubMed Web of Science ®Google Scholar
• D'Amico D, Carbone D, Mitsudomi T, et al. High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene 1992; 7: 339–346
   PubMed Web of Science ®Google Scholar
• Sameshima Y, Matsuno Y, Hirohashi S, et al. Alterations of the p53 gene are common and critical events for the maintenance of malignant phenotypes in small-cell lung carcinoma. Oncogene 1992; 7: 451–457
   PubMed Web of Science ®Google Scholar
• Wang N P, To H, Lee W-H, et al. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene 1993; 8: 279–88
   PubMed Web of Science ®Google Scholar
• Malkin D, Li F P, Strong L C, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233–1238
   PubMed Web of Science ®Google Scholar
• Sidransky D, Von Eschenbach A, Tsai Y C, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991; 252: 706–709
   PubMed Web of Science ®Google Scholar
• Diller L, Kassel J, Nelson C, et al. p53 functions as a cell cycle control protein in osteosarcoma. Mol Cell Biol 1990; 10: 5772–5781
   PubMed Web of Science ®Google Scholar
• Oliner J D, Kinzler K W, Meltzer P S, et al. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80–83
   PubMed Web of Science ®Google Scholar
• Chabner B A, Myers C E. Clinical pharmacology of cancer chemotherapy. Cancer-Principles and Practice of Oncology, 2nd ed, V T DeVita, S Hellman, S A Rosenberg. JB Lippincott, Philadelphia 1985; 287–328
   Google Scholar